10:15 AM EDT, 05/07/2024 (MT Newswires) -- MoonLake Immunotherapeutics ( MLTX ) reported Q1 net loss attributable to controlling interests shareholders Tuesday of $0.22 per diluted share, compared to $0.12 a year earlier.

Analysts polled by Capital IQ expected a per-share loss of $0.20.

The company did not report any revenue for the quarter ended March 31.

As of March 31, the company said it had $547.1 million in cash, cash equivalents and short-term marketable debt securities.

Price: 43.88, Change: -0.64, Percent Change: -1.44